Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers
- 5 August 1999
- Vol. 18 (1-2) , 160-172
- https://doi.org/10.1016/s0264-410x(99)00216-9
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccineVaccine, 1996
- Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, ChileVaccine, 1995
- Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodiesJournal of Medical Microbiology, 1994
- New strategies for using mucosal vaccination to achieve more effective immunizationVaccine, 1994
- Humoral Immune Response Patterns of Human Mucosae: Induction and Relation to Bacterial Respiratory Tract InfectionsThe Journal of Infectious Diseases, 1992
- Effect of outer membrane vesicle vaccine against group B meningococcal disease in NorwayThe Lancet, 1991
- Serotype-specific outbreak of group B meningococcal disease in Iquique, ChileEpidemiology and Infection, 1990
- Lipooligosaccharides (LOS) of Neisseria gonorrhoeae and Neisseria meningitidis have components that are immunochemically similar to precursors of human blood group antigens. Carbohydrate sequence specificity of the mouse monoclonal antibodies that recognize crossreacting antigens on LOS and human erythrocytes.The Journal of Experimental Medicine, 1988
- Complex of Meningococcal Group B Polysaccharide and Type 2 Outer Membrane Protein Immunogenic in ManJournal of Clinical Investigation, 1979
- HUMAN IMMUNITY TO THE MENINGOCOCCUSThe Journal of Experimental Medicine, 1969